Critical appraisal of adalimumab in the treatment of chronic plaque psoriasis
Danielle Nicolazzo,1 Franz Kerdel,1 Francisco Kerdel1,2 1Florida Academic Dermatology Centers, The University of Miami Hospital, Miami, FL, USA; 2Florida International University, Miami, FL, USA Abstract: Psoriasis is a chronic inflammatory disease estimated to affect 1%–3% of the worldw...
Guardado en:
Autores principales: | Nicolazzo D, Kerdel F |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://doaj.org/article/996958c3b99d48eca82e859392d8777d |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
The effect of biosimilar administration on clinical outcomes in patients with adalimumab‐controlled psoriasis
por: M. Panahi, et al.
Publicado: (2021) -
Plaque psoriasis in children and adolescents – the role of etanercept
por: Ricceri F, et al.
Publicado: (2012) -
Emerging treatment options for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis: evaluating bimekizumab and its therapeutic potential [Corrigendum]
por: Chiricozzi A, et al.
Publicado: (2019) -
Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date
por: Machado Á, et al.
Publicado: (2018) -
Emerging treatment options for psoriasis
por: Taheri A, et al.
Publicado: (2014)